Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10540967rdf:typepubmed:Citationlld:pubmed
pubmed-article:10540967lifeskim:mentionsumls-concept:C0289174lld:lifeskim
pubmed-article:10540967lifeskim:mentionsumls-concept:C1415803lld:lifeskim
pubmed-article:10540967lifeskim:mentionsumls-concept:C1621296lld:lifeskim
pubmed-article:10540967pubmed:issue4lld:pubmed
pubmed-article:10540967pubmed:dateCreated1999-11-30lld:pubmed
pubmed-article:10540967pubmed:abstractTextThree series of new 9-substituted 1,2,3,4-tetrahydro-beta-carbolin-1-ones with 2-, 3- and 4-membered alkyl chain (1, 2 and 3, respectively) were synthesized, and the effect of some structural modifications on their 5-HT1A and 5-HT2A receptor affinities and functional in vivo properties was discussed. Radioligand binding measurements showed that the majority of compounds had a distinct affinity for 5-HT1A (1b, 2a, 2b, 2c, 3b; Ki = 0.3-64 nM) and 5-HT2A receptors (1b, 2b, 2c, 3b; Ki = 0.9-80 nM). The most potent 5-HT1A (1b, 2a, 2b, 3b) and 5-HT2A (1b, 2b, 3b) ligands were evaluated in in vivo tests. The obtained results indicate that 1,2,3,4-tetrahydro-beta-carbolin-1-ones containing 1-(o-methoxyphenyl)piperazine (1-3b) show pharmacological profile of 5-HT1A postsynaptic antagonists (with very weak agonistic component) and 5-HT2A antagonists, compound with 1,2,3,4-tetrahydroisoquinoline (2a) is a pure 5-HT1A postsynaptic antagonist. Summing up, the connection of 1,2,3,4-tetrahydro-beta-carbolin-1-one moiety through the 2-4-membered alkyl spacer with 1-(o-methoxyphenyl)-piperazine, which is present in a variety of 5-HT1A ligands, allowed us to obtain the compounds with high and equal affinity for 5-HT1A/5-HT2A receptors and the expected functional properties, i.e. distinct antagonistic and weak agonistic activity at 5-HT1A postsynaptic receptors and antagonistic at 5-HT2A ones.lld:pubmed
pubmed-article:10540967pubmed:languageenglld:pubmed
pubmed-article:10540967pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10540967pubmed:citationSubsetIMlld:pubmed
pubmed-article:10540967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10540967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10540967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10540967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10540967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10540967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10540967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10540967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10540967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10540967pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10540967pubmed:statusMEDLINElld:pubmed
pubmed-article:10540967pubmed:issn1230-6002lld:pubmed
pubmed-article:10540967pubmed:authorpubmed-author:BoksaJJlld:pubmed
pubmed-article:10540967pubmed:authorpubmed-author:Weso?owskaAAlld:pubmed
pubmed-article:10540967pubmed:authorpubmed-author:Charakchieva-...lld:pubmed
pubmed-article:10540967pubmed:authorpubmed-author:MokroszM JMJlld:pubmed
pubmed-article:10540967pubmed:authorpubmed-author:BoryczJJlld:pubmed
pubmed-article:10540967pubmed:issnTypePrintlld:pubmed
pubmed-article:10540967pubmed:volume51lld:pubmed
pubmed-article:10540967pubmed:ownerNLMlld:pubmed
pubmed-article:10540967pubmed:authorsCompleteYlld:pubmed
pubmed-article:10540967pubmed:pagination351-6lld:pubmed
pubmed-article:10540967pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:meshHeadingpubmed-meshheading:10540967...lld:pubmed
pubmed-article:10540967pubmed:articleTitle9-substituted 1,2,3,4-tetrahydro-beta-carbolin-1-ones, new 5-HT1A and 5-HT2A receptor ligands.lld:pubmed
pubmed-article:10540967pubmed:affiliationDepartment of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Sciences, Kraków.lld:pubmed
pubmed-article:10540967pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10540967pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed